Silexion reports preclinical data: SIL-204 systemic admin reduces pancreatic tumor growth ~50%

Silexion Therapeutics Corp

Extended-release SIL-204 reduced tumor growth ~50% after 30 days; ~50% of tumors showed complete necrosis in G12D xenografts.
Subcutaneous SIL-204 inhibited tumor growth in mouse metastatic pancreatic orthotopic models.
Single systemic dose maintained drug levels in rat plasma and tissues for over 56 days.
SIL-204 inhibits multiple KRAS mutations: G12D, G12V, G12R, Q61H, and G13D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.